Emily Ycasas
Family · San Diego, CANPI 1033841861
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,298 of the $7,309 with a category attached, or 86.2%. 33 manufacturers reported payments, led by Boston Scientific at 25.3% of the total. Reporting peaked in 2024 at $3,253 and has fallen 57.2% since, to $1,393 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $54.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abbott$908
- Novo Nordisk$440
- Heartflow, Inc.$439
- Edwards Lifesciences$368
- Johnson & Johnson$307
- plus $3K from 27 others
What the payments were for
- Grants$951%
- Travel & lodging$91713%
- Food & beverage$6,29886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $1,849 |
| Abbott | 15 | $908 |
| Novo Nordisk | 7 | $440 |
| Heartflow, Inc. | 3 | $439 |
| Edwards Lifesciences | 3 | $368 |
| Johnson & Johnson | 4 | $307 |
| Abiomed | 2 | $293 |
| Impulse Dynamics (USA) Inc. | 2 | $251 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $248 |
| AbbVie | 2 | $240 |
| Amgen | 5 | $207 |
| Actelion Pharmaceuticals US, Inc. | 18 | $172 |
| Novartis | 7 | $161 |
| Shockwave Medical, Inc | 1 | $158 |
| Merck | 3 | $129 |
| Exact Sciences | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Amarin Pharma, Inc. | 1 | $111 |
| Phathom Pharmaceuticals, Inc. | 1 | $111 |
| Bayer | 4 | $91 |
| AstraZeneca | 4 | $87 |
| Alnylam Pharmaceuticals Inc. | 3 | $64 |
| Cvrx, Inc. | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Boehringer Ingelheim | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| GSK | 1 | $16 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$973
- OPTIMIZER$503
- FFRct$439
- WATCHMAN Access System$407
- AVEIR$390
- SAPIEN 3 Ultra RESILIA$268
- XARELTO$254
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$158
- MitraClip$148
- Impella$144
- KRYSTEXXA$135
- Farapulse$127
- Cologuard Collection Kit$125
- UBRELVY$124
- INJECTAFER$124
- Austedo XR$122
- RYBELSUS$121
- LINZESS$116
- Vascepa$111
- VOQUEZNA$111
How this compares
$7,309 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $39,729 |
| XareltoRivaroxaban | 24 | $20,242 |
| Repatha SureclickEvolocumab | 20 | $11,776 |
| Atorvastatin Calcium | 138 | $1,917 |
| Carvedilol | 88 | $681 |
| Ranolazine ErRanolazine | 15 | $632 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 49 | $562 |
| Metoprolol Succinate | 51 | $551 |
| Chlorthalidone | 12 | $371 |
| Losartan Potassium | 53 | $369 |
| Amlodipine Besylate | 74 | $339 |
| Nitroglycerin | 24 | $261 |
| Furosemide | 49 | $216 |
| Metoprolol Tartrate | 48 | $211 |
| Hydralazine Hcl | 23 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $307 | $20,24224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Diego
- Dawn MeyerSan Diego$270K
- Erin DwyerSan Diego$189K
- Lizaveta NikitsinaSan Diego$36K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Jennifer KangCerritos$255K
- Phyllis CasonLos Angeles$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.